Blue Trust Inc. Increases Stake in Smith & Nephew plc (NYSE:SNN)

Blue Trust Inc. boosted its stake in Smith & Nephew plc (NYSE:SNN) by 26.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,871 shares of the medical equipment provider’s stock after purchasing an additional 1,213 shares during the period. Blue Trust Inc.’s holdings in Smith & Nephew were worth $144,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in SNN. River Road Asset Management LLC purchased a new stake in shares of Smith & Nephew in the 3rd quarter worth about $38,588,000. Point72 DIFC Ltd purchased a new position in shares of Smith & Nephew in the third quarter worth $7,200,000. Raymond James & Associates boosted its holdings in shares of Smith & Nephew by 172.1% during the 3rd quarter. Raymond James & Associates now owns 128,854 shares of the medical equipment provider’s stock valued at $4,013,000 after acquiring an additional 81,500 shares during the last quarter. Maverick Capital Ltd. bought a new stake in Smith & Nephew in the 3rd quarter worth approximately $2,086,000. Finally, Crossmark Global Holdings Inc. increased its position in Smith & Nephew by 63.7% during the third quarter. Crossmark Global Holdings Inc. now owns 112,859 shares of the medical equipment provider’s stock valued at $3,515,000 after acquiring an additional 43,924 shares during the last quarter. 25.64% of the stock is owned by hedge funds and other institutional investors.

Smith & Nephew Stock Performance

NYSE:SNN opened at $26.13 on Thursday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. The stock’s fifty day moving average is $25.06 and its 200 day moving average is $27.60. Smith & Nephew plc has a fifty-two week low of $23.65 and a fifty-two week high of $31.72.

Analysts Set New Price Targets

SNN has been the topic of several analyst reports. StockNews.com cut shares of Smith & Nephew from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th. Berenberg Bank downgraded shares of Smith & Nephew from a “buy” rating to a “hold” rating in a report on Wednesday, November 6th. Finally, Deutsche Bank Aktiengesellschaft lowered Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Friday, November 1st.

About Smith & Nephew

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.